Phase 3
Completed N=124
Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis
Source: ClinicalTrials.gov NCT02595073 ↗Enrolled (actual)
124
Serious AEs
0.0%
Results posted
Dec 2018
Primary outcomePrimary: The Number of Patients in Each Treatment Group That Have Clinical Success — 21; 27 Participants — p=0.3353
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
Efficacy and Safety of DSXS (Taro Pharmaceuticals, U.S.A., Inc.) in Patients with Moderate to Severe Atopic Dermatitis
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY The Number of Patients in Each Treatment Group That Have Clinical Success |
21; 27 | 0.3353 |
| SECONDARY Change From Baseline in %BSA Affected at Day 28 ± 2 |
-13.81; -13.24 | 0.6190 |
Eligibility Criteria
Inclusion Criteria
- male and non-pregnant females, age 6 months or older, with a confirmed diagnosis of moderate to severe atopic dermatitis (AD)
Exclusion Criteria
- Lacks stable diagnosis of atopic dermatitis or has been diagnosed with mild atopic dermatitis.
Data sourced from ClinicalTrials.gov (NCT02595073). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.